UNSPSC 51142435: Sumatriptan succinate

This classification denotes a serotonin agonist with the molecular formula C14H21N3O2S.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J8BDZ68989, chemically known as 1h-indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-n-methyl- but more generally known as sumatriptan succinate, which bears US NIH Compound Identifier 5358. European Medicines Agency schedules Sumatriptan succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15437MIG.

UNSPSC 51142435 Sumatriptan succinate is a Commodity code that encompasses branded and generic pharmaceutical products procured by state and local health authorities, though recent state and local solicitations tagged with this code do not show specific demand for sumatriptan itself. Instead, the tagged opportunities reflect broader pharmaceutical procurement activity where state and local health agencies are sourcing multiple drug categories through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves establishing contracts for pharmaceutical supply, managing relationships with authorized wholesalers and manufacturers, and ensuring compliance with FDA requirements, Good Manufacturing Practices, and the Drug Supply Chain Security Act.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems with quarterly deliveries and a two-year initial contract term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program serving self-insured state employee health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and maintain pricing in multiple formats (flat, net, or WAC-minus) with a 3 percent administrative fee and performance penalties for compliance failures. These solicitations show state and local preference for multivendor or multi-award structures and emphasis on wholesale distribution channels rather than direct institutional supply.